Granisetron Kabi (Granisetron Hydrochloride)

Granisetron Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of acute chemotherapy‑induced nausea and vomiting (CINV) following moderately or highly emetogenic regimens.
• Prevention of delayed CINV when administered as part of a multimodal antiemetic protocol.
• Prevention of postoperative nausea and vomiting (PONV) after general anesthesia.
• Adjunct therapy in patients receiving radiation therapy who are at risk for emesis.
• Use in pediatric oncology patients when dosing is determined by a qualified clinician.

The safety profile of Granisetron Kabi includes both common and less frequent serious adverse events.

Common

• Headache – mild to moderate intensity.
• Constipation – may be transient.
• Diarrhea – occasional and self‑limiting.
• Dizziness – usually resolves without intervention.
• Fatigue – generally mild.

Serious

• Cardiac arrhythmias, including QT interval prolongation, which may be clinically significant.
• Severe hypersensitivity reactions such as anaphylaxis or angioedema.
• Seizures – rare but reported in isolated cases.

When prescribing Granisetron Kabi, clinicians should consider several precautionary measures to ensure safe use.

• Assess baseline cardiac status, especially QT interval, as 5‑HT3 antagonists may affect cardiac repolarization.
• Use cautiously in patients with a history of severe constipation or bowel obstruction.
• Evaluate renal and hepatic function; dose adjustments may be required in significant impairment.
• Avoid use in patients with known hypersensitivity to granisetron or any component of the formulation.
• Consider potential risks when administered concomitantly with other QT‑prolonging agents.
• Review pregnancy and lactation status, as safety data are limited.

Granisetron Kabi can interact with other medications, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other QT‑prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics).
• Co‑administration with potent CYP3A4 inhibitors that may increase granisetron plasma levels.
• Use with other serotonergic agents that could increase the risk of serotonin syndrome.

Use with caution

• Combination with other antiemetics (e.g., dexamethasone, aprepitant) may require dose adjustments.
• Concurrent administration with drugs that affect electrolyte balance, such as diuretics, may influence cardiac risk.
• Use with anesthetic agents that have emetogenic potential, monitoring for additive effects.